导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.00% | 1305/4773 |
| 近一周 | -0.86% | 1347/5465 |
| 近一月 | -2.10% | 1476/5421 |
| 近一季 | -4.41% | 1810/5231 |
| 近半年 | -2.76% | 2264/4920 |
| 近一年 | 9.79% | 1163/4394 |
| 近两年 | 65.18% | 1103/2954 |
| 近三年 | 44.42% | 664/2253 |
| 成立以来 | 161.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.00% 1392/4961 |
12.49% 2169/5312 |
- - |
- - |
| 2025 | 26.50% 1627/4813 |
1.18% 1678/3635 |
3.26% 1078/4076 |
18.75% 2252/4524 |
1.96% 1129/4813 |
| 2024 | 11.07% 1348/3463 |
-1.73% 1267/2808 |
-0.79% 837/3014 |
13.71% 2126/3129 |
0.19% 1255/3463 |
| 2023 | 0.21% 419/2656 |
5.91% 744/2280 |
-2.10% 558/2385 |
-1.25% 498/2515 |
-2.13% 431/2655 |
| 2022 | -13.90% 348/2207 |
-10.88% 446/1919 |
4.69% 982/2016 |
-10.53% 419/2113 |
3.14% 763/2208 |
| 2021 | 17.59% 228/1822 |
3.97% 64/580 |
7.24% 425/659 |
3.72% 151/704 |
1.69% 836/1822 |
| 2020 | 40.20% 313/1250 |
0.83% 144/419 |
21.75% 255/466 |
11.50% 216/517 |
2.43% 472/554 |
| 2019 | 37.13% 341/1092 |
28.36% 472/1149 |
-3.28% 602/1231 |
3.12% 251/390 |
7.12% 272/410 |
| 2018 | -22.51% 242/834 |
- - |
- - |
- - |
-9.67% 275/1080 |
| 2017 | -0.70% 485/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.96% 152/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证500指数增强A VS. 长安沪深300非周期A(740101) |